2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1367

Fibroblast-like Synoviocytes Shape and Perpetuate the Inflammatory Immune Responses Associated with Antibiotic-Refractory Lyme Arthritis.
Abstract Number: 69

Fibrofog in Mild and Severe Variants of Fibromyalgia
Abstract Number: 75

Fibromyalgia and Positional Cervical Cord Compression Differ Only By Autonomic Nervous System Consequences: A Double-Blinded, Prospective Study
Abstract Number: 71

Fibromyalgia Dysautonomia and Distress. Correlation Between the Newly Developed Composite Autonomic Symptoms (COMPASS-31) Questionnaire and the Fibromyalgia Polysymptomatic Distress Scale
Abstract Number: 1690

Fibromyalgia in Spondyloarthritis: Impact on Disease Activity Assessment
Abstract Number: 66

Fibromyalgia Patients Identify More Causes of Disease Flare Ups Than RA Patients
Abstract Number: 3090

Fibromyalgia Predicts Two-Year Changes in Functional Status in Rheumatoid Arthritis Patients
Abstract Number: 2763

Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, Shows Similar Pharmacokinetics and Pharmacodynamics Profiles in Japanese and Caucasian Healthy Volunteers
Abstract Number: 1049

Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective As Monotherapy in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
Abstract Number: 1048

Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
Abstract Number: 2119

Findings and Therapeutic Impact of Magnetic Resonance Imaging (MRI) Studies for Patients with Lower Back Pain with Neurologic Symptoms. Are We Choosing Wisely?
Abstract Number: 2597

Fine Specificity of Anti-Citrullinated Peptide Antibodies Is Associated with Left Ventricular Mass Index in Rheumatoid Arthritis Patients without Cardiovascular Disease
Abstract Number: 1742

Fingerprint Biomarkers of Type I and III Collagen in Axial Spondyloarthropathy (axSpA) and Psoriatic Arthritis (PsA). Association with Disease Activity and Diagnostic Capacity
Abstract Number: 458

First Year Canadian Experience with Subcutaneous Abatacept in Routine Practice for the Treatment of Patients with Rheumatoid Arthritis: Data from the Orencia Response Program (ORP) Network
Abstract Number: 1327

Five-Year Follow-up of Radiographic Sacroiliitis: Progression As Well As Improvement?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].